Resources with keywords: JYNNEOS vaccine
Autochthonous clade Ib transmission confirmed in EU/EEA. Outside Africa, 97% of cases are male, 89% MSM — pattern relevant to clinical triage and ED screening protocols. Laboratory personnel should note that standard dermatopathology laboratory procedures (formalin fixation) adequately inactivate orthopoxviruses; however, unfixed specimens require BSL-2 handling. ECDC recommends JYNNEOS post-exposure prophylaxis for HCWs with unprotected exposure within 4 days.
HCWs caring for mpox patients without adequate PPE (gown, gloves, eye protection, N95 for aerosol-generating procedures) face direct contact transmission risk. All clades (Ia, Ib, IIb) circulating globally. Clade Ib recombinant with Ia/IIb genomic elements detected in February 2026; biological behavior not yet fully characterized. Diagnostic laboratory personnel handling skin lesion specimens must use BSL-2 enhanced precautions. JYNNEOS vaccine recommended for HCWs at occupational risk.
